1. Home
  2. TLSA vs ZSQR Comparison

TLSA vs ZSQR Comparison

Compare TLSA & ZSQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

N/A

Current Price

$0.68

Market Cap

145.1M

Sector

Health Care

ML Signal

N/A

Logo Z Squared Inc. Common Stock

ZSQR

Z Squared Inc. Common Stock

N/A

Current Price

$1.85

Market Cap

147.9M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
TLSA
ZSQR
Founded
2013
2022
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
145.1M
147.9M
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
TLSA
ZSQR
Price
$0.68
$1.85
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
★ $7.87
N/A
AVG Volume (30 Days)
★ 522.3K
303.6K
Earning Date
05-01-2026
12-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 50.27
EPS
★ N/A
N/A
Revenue
N/A
★ $1,363,045.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.55
$1.83
52 Week High
$1.90
$16.62

Technical Indicators

Market Signals
Indicator
TLSA
ZSQR
Relative Strength Index (RSI) 46.12 30.02
Support Level $0.57 N/A
Resistance Level $1.21 $4.64
Average True Range (ATR) 0.10 0.42
MACD 0.01 -0.12
Stochastic Oscillator 55.24 1.68

Price Performance

Historical Comparison
TLSA
ZSQR

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.

About ZSQR Z Squared Inc. Common Stock

Z Squared Inc is a computing infrastructure company operating computing equipment and expanding into AI infrastructure. The Company's idea is to build on three principles: guide with power by acquiring operating sites where power is already flowing; build for AI workloads by converting that capacity into AI-ready colocation where the customer brings the compute and runs what it needs; and scale with discipline by deploying conversion capital site by site, against signed contracts and operational readiness.

Share on Social Networks: